Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26094112 | 0.88 | — | — | |
| SCHEMBL16390870 | 0.85 | CHRM2 (0.35) | CHRM2FFAR4CHRM1 | |
| SCHEMBL26096649 | 0.84 | FFAR4 (0.35) | FFAR4 | |
| SCHEMBL26094735 | 0.83 | NOTUM (0.33) | FFAR4NOTUM | |
| SCHEMBL26097421 | 0.83 | SLC6A9 (0.34) | CHRM4FFAR4 | |
| SCHEMBL3762977 | 0.82 | FFAR4 (0.38) | CHRM4FFAR4NOTUM | |
| SCHEMBL3478584 | 0.82 | NR1H2 (0.39) | NOTUM | |
| SCHEMBL384271 | 0.81 | LIPG (0.39) | — | |
| SCHEMBL14159644 | 0.81 | CHRM4 (0.33) | CHRM4 | |
| SCHEMBL26096369 | 0.81 | FFAR4 (0.35) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CHRM2 3335/4885CHRM4 3695/4885FFAR4 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.